214 related articles for article (PubMed ID: 33077485)
1. Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Kuznetsoff JN; Owens DA; Lopez A; Rodriguez DA; Chee NT; Kurtenbach S; Bilbao D; Roberts ER; Volmar CH; Wahlestedt C; Brothers SP; Harbour JW
Mol Cancer Res; 2021 Feb; 19(2):215-222. PubMed ID: 33077485
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Landreville S; Agapova OA; Matatall KA; Kneass ZT; Onken MD; Lee RS; Bowcock AM; Harbour JW
Clin Cancer Res; 2012 Jan; 18(2):408-16. PubMed ID: 22038994
[TBL] [Abstract][Full Text] [Related]
3. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
Kuznetsov JN; Aguero TH; Owens DA; Kurtenbach S; Field MG; Durante MA; Rodriguez DA; King ML; Harbour JW
Sci Adv; 2019 Sep; 5(9):eaax1738. PubMed ID: 31555735
[TBL] [Abstract][Full Text] [Related]
4. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
Han A; Purwin TJ; Bechtel N; Liao C; Chua V; Seifert E; Sato T; Schug ZT; Speicher DW; Harbour JW; Aplin AE
Oncogene; 2021 Jan; 40(3):618-632. PubMed ID: 33208912
[TBL] [Abstract][Full Text] [Related]
5. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
[TBL] [Abstract][Full Text] [Related]
6. BAP1 loss augments sensitivity to BET inhibitors in cancer cells.
Xu YY; Ren ZL; Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Luo X; Liu SW; Li YL; Yu L
Acta Pharmacol Sin; 2022 Jul; 43(7):1803-1815. PubMed ID: 34737422
[TBL] [Abstract][Full Text] [Related]
7. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
8. Biological Mechanisms and Clinical Significance of
Carbone M; Harbour JW; Brugarolas J; Bononi A; Pagano I; Dey A; Krausz T; Pass HI; Yang H; Gaudino G
Cancer Discov; 2020 Aug; 10(8):1103-1120. PubMed ID: 32690542
[TBL] [Abstract][Full Text] [Related]
9. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma.
Shah AA; Bourne TD; Murali R
Pathology; 2013 Dec; 45(7):651-6. PubMed ID: 24247622
[TBL] [Abstract][Full Text] [Related]
10. Tumours associated with BAP1 mutations.
Murali R; Wiesner T; Scolyer RA
Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
[TBL] [Abstract][Full Text] [Related]
11. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.
Carbone M; Ferris LK; Baumann F; Napolitano A; Lum CA; Flores EG; Gaudino G; Powers A; Bryant-Greenwood P; Krausz T; Hyjek E; Tate R; Friedberg J; Weigel T; Pass HI; Yang H
J Transl Med; 2012 Aug; 10():179. PubMed ID: 22935333
[TBL] [Abstract][Full Text] [Related]
12. Germline BAP1 mutations predispose to malignant mesothelioma.
Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
[TBL] [Abstract][Full Text] [Related]
13. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Sacco JJ; Kenyani J; Butt Z; Carter R; Chew HY; Cheeseman LP; Darling S; Denny M; Urbé S; Clague MJ; Coulson JM
Oncotarget; 2015 May; 6(15):13757-71. PubMed ID: 25970771
[TBL] [Abstract][Full Text] [Related]
14. Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.
Marušić Z; Buljan M; Busam KJ
J Cutan Pathol; 2015 Jun; 42(6):406-12. PubMed ID: 25902915
[TBL] [Abstract][Full Text] [Related]
15. BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells.
Pan H; Jia R; Zhang L; Xu S; Wu Q; Song X; Zhang H; Ge S; Xu XL; Fan X
Int J Biochem Cell Biol; 2015 Mar; 60():176-84. PubMed ID: 25582751
[TBL] [Abstract][Full Text] [Related]
16. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
Wang XY; Wang Z; Huang JB; Ren XD; Ye D; Zhu WW; Qin LX
Tumour Biol; 2017 Jun; 39(6):1010428317699111. PubMed ID: 28618948
[TBL] [Abstract][Full Text] [Related]
17. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma.
Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD
BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in prognostic and predictive testing in uveal melanoma.
Field MG; Harbour JW
Curr Opin Ophthalmol; 2014 May; 25(3):234-9. PubMed ID: 24713608
[TBL] [Abstract][Full Text] [Related]
19. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
[TBL] [Abstract][Full Text] [Related]
20. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V; Han A; Bechtel N; Purwin TJ; Hunter E; Liao C; Harbour JW; Aplin AE
Pigment Cell Melanoma Res; 2022 Jan; 35(1):78-87. PubMed ID: 34347929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
